Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SIRAGUSA, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.040
EU - Europa 12.462
AS - Asia 10.394
SA - Sud America 1.823
AF - Africa 302
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 14
Totale 48.063
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.606
SG - Singapore 3.890
IT - Italia 2.934
RU - Federazione Russa 2.919
CN - Cina 2.438
BR - Brasile 1.436
DE - Germania 1.372
FI - Finlandia 1.067
HK - Hong Kong 1.019
VN - Vietnam 938
UA - Ucraina 933
PL - Polonia 703
GB - Regno Unito 582
FR - Francia 568
JP - Giappone 425
IE - Irlanda 389
BD - Bangladesh 384
SE - Svezia 295
IN - India 264
CA - Canada 249
KR - Corea 226
NL - Olanda 174
TR - Turchia 143
AR - Argentina 132
IQ - Iraq 104
MX - Messico 89
AT - Austria 86
ES - Italia 83
RO - Romania 82
BE - Belgio 74
CI - Costa d'Avorio 71
PK - Pakistan 69
ZA - Sudafrica 67
ID - Indonesia 66
UZ - Uzbekistan 57
EC - Ecuador 53
VE - Venezuela 48
CO - Colombia 46
IR - Iran 45
MA - Marocco 39
SA - Arabia Saudita 39
CL - Cile 38
CH - Svizzera 37
MY - Malesia 36
GR - Grecia 31
PY - Paraguay 28
EG - Egitto 26
JO - Giordania 26
AE - Emirati Arabi Uniti 23
CR - Costa Rica 23
PH - Filippine 23
UY - Uruguay 23
KE - Kenya 22
DZ - Algeria 21
JM - Giamaica 21
LT - Lituania 21
ET - Etiopia 20
IL - Israele 20
TW - Taiwan 19
AU - Australia 18
NP - Nepal 17
KZ - Kazakistan 16
AL - Albania 15
QA - Qatar 15
CZ - Repubblica Ceca 14
TN - Tunisia 13
BG - Bulgaria 12
LB - Libano 12
OM - Oman 12
AZ - Azerbaigian 11
DO - Repubblica Dominicana 11
PE - Perù 10
DK - Danimarca 9
MD - Moldavia 9
RS - Serbia 9
BH - Bahrain 8
BO - Bolivia 8
EU - Europa 8
HN - Honduras 7
MM - Myanmar 7
NZ - Nuova Zelanda 7
PT - Portogallo 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
AO - Angola 6
BY - Bielorussia 6
HR - Croazia 6
HU - Ungheria 6
KG - Kirghizistan 6
SY - Repubblica araba siriana 6
TH - Thailandia 6
GT - Guatemala 5
KH - Cambogia 5
KW - Kuwait 5
PR - Porto Rico 5
PA - Panama 4
PS - Palestinian Territory 4
XK - ???statistics.table.value.countryCode.XK??? 4
BA - Bosnia-Erzegovina 3
BF - Burkina Faso 3
Totale 48.011
Salva come PNG Salva come JPEG
Città #
Ashburn 2.827
Singapore 2.496
Fairfield 2.385
San Jose 1.427
Chandler 1.248
Woodbridge 1.246
Houston 1.226
Wilmington 999
Hong Kong 975
Seattle 938
Cambridge 756
Ann Arbor 633
Zgierz 599
Palermo 498
Moscow 489
Council Bluffs 483
Jacksonville 465
Beijing 446
Tokyo 397
Medford 388
Dublin 382
Santa Clara 353
Helsinki 321
Los Angeles 321
Frankfurt am Main 311
Ho Chi Minh City 300
Des Moines 294
New York 283
Dallas 267
Lauterbourg 260
Princeton 256
Boardman 254
Altamura 251
Nanjing 237
Hanoi 236
Hefei 186
Lawrence 186
San Diego 174
Milan 173
Dearborn 146
Buffalo 144
The Dalles 140
Rome 134
São Paulo 132
Tulsa 119
Chicago 99
London 89
Orem 89
Ludwigshafen am Rhein 88
Shenyang 80
Phoenix 75
Columbus 72
Nuremberg 72
Abidjan 70
Brussels 70
Tianjin 69
Nanchang 66
Amsterdam 62
Stockholm 61
Hebei 60
Warsaw 60
Brooklyn 57
Seongnam 56
Changsha 52
Atlanta 51
Denver 51
Montreal 49
Zhengzhou 49
Naperville 48
Toronto 47
Jinan 46
Washington 46
Guangzhou 45
Chennai 44
Lappeenranta 43
Izmir 42
Jiaxing 42
Rio de Janeiro 41
Tashkent 41
San Paolo di Civitate 40
Shanghai 39
Baghdad 38
Bremen 38
Mumbai 38
Munich 38
Poplar 36
Vienna 36
Da Nang 34
Falls Church 34
Redwood City 34
Verona 34
Cardiff 32
Piscataway 32
Haiphong 31
Johannesburg 31
Ningbo 31
Porto Alegre 31
Seoul 31
Kumar 30
City of London 29
Totale 29.530
Salva come PNG Salva come JPEG
Nome #
Curva da carico orale di metionina nella valutazione di pazienti affetti da patologia trombotica 656
Cardiovascular events and intensity of treatment in polycythemia vera. 647
Absolute Lymphocyte Count Is Unrelated to Overall Survival in Newly Diagnosed Elderly Patients with Multiple Myeloma Treated with Immunomodulatory Drugs. 489
Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses 358
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. 347
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. 345
Clinical phenotype and response to different lines of therapy in elderly with immune thrombocytopenia: A retrospective study 327
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 319
Comparison between thrombotic risk scores in Essential Thrombocythemia and survival implications 304
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity 287
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 278
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system 272
Health-related quality of life and psychological well-being in elderly patients with haemophilia 265
Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. 263
Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results from a multicentre cross-sectional study 263
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report 261
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. 259
Acquired haemophilia in cancer: A systematic and critical literature review 258
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature 255
Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia 252
Successful Treatment of Gastrointestinal Bleeding With Recombinant Factor VIIa After Kidney Transplantation in Patients With Pancytopenia. 248
EGFR genomic alterations in cancer: prognostic and predictive values 241
Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study 241
Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia 241
Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry 241
Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management 238
Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario 234
Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry 232
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience 232
Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS) 231
Erythrocyte deformability and hemorheological profile in multiple myeloma 231
null 231
Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma 231
Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study 227
Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study 226
Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature 226
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study 225
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis 225
Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series 220
Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies 218
The risk of recurrent cardiovascular events in patients with increased plasma homocysteine levels is reduced by short but not long-term therapy with folate and B vitamins. 216
Peri-operative bridgning therapy with low molecular weight heparin in patients requiring interruption of long-term oral anticoagulant therapy 216
Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report. 216
Antimicorbial prophylaxis in patients with immune thrombocytopenia treated with rituximab:a retrospective analysis 216
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy 214
Immunosenescence and lymphomagenesis 214
Deferral of assessment of pulmonary embolism 213
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 212
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate 212
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 210
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis 208
Multiple Myeloma-Derived Extracellular Vesicles Induce Osteoclastogenesis through the Activation of the XBP1/IRE1α Axis 208
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients 207
Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin 205
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation 204
Clinical implications of discordant early molecular responses in CML patients treated with imatinib 204
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease 203
Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up 203
Aspirin for preventing the recurrence of venous thromboembolism 201
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 200
Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly. 200
Rivaroxaban for thromboprophylaxis in acutely ill medical patients 199
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA. 199
Integrated Multi-Omic Profiling of Immune, Soluble, and Microbial Signatures Identifies Predictors of Multiple Myeloma Evolution 198
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study 198
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 197
PERIOPERATIVE BRIDGING THERAPY WITH LOW MOLECULAR WEIGH HEPARIN IN PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY 197
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 196
ENDOGENOUS THROMBIN POTENTIAL IN PATIENTS WITH IDIOPATHIC VENOUS THROMBOSIS 195
Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma 195
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study 194
Long term outcomes of patients with cerebral vein thrombosis: a multicenter study. 193
Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, of both? 192
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. 192
Cardio-oncology in multiple myeloma: is it time for a specific focus? 192
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. 191
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogues 191
Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins 189
Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS Study 189
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results 189
La profilassi chirurgica di pazienti con carenza congenita di FVII 187
Gastrointestinal bleeding in patients with von Willebrand disease; how long we can wait for surgery? 187
Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins 185
JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 185
Mapping Cell-Cell Communication Dynamics Across the Spectrum of Multiple Myeloma Evolution Using Single-Cell Transcriptomics 184
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 184
Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients 184
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 184
Cardiovascular risk factor in MPN patients 184
D-dimer testing: advantages and limitation in emergency medicine for managing acute venous thromboembolism 182
Absence of Residual Vein Thrombosis after an Episode of Idiopathic Deep Vein Thrombosis: Short-Term Anticoagulation Is Safe. The "Extended Dacus Study". 181
Emotions and Opinions of Adult Patients with Haemophilia During the COVID-19 (Coronavirus Disease 2019) Pandemic Caused by SARS-CoV-2: A Monocentric Survey 179
ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER STUDY 178
Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements 177
PNEUMOCYSTIS JIROVECI PNEUMONIA IN HEMATOLOGICAL PATIENTS: A SINGLE INSTITUTION EXPERIENCE 177
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors 175
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep 175
Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer. 173
Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy 172
Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association 172
Totale 23.017
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.856
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.856
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.008 195 591 79 130 84 160 148 155 350 396 204 516
2022/20233.912 392 733 96 405 411 619 225 307 449 45 157 73
2023/20242.042 91 286 167 280 153 356 215 88 26 58 39 283
2024/20254.822 164 268 242 459 195 164 378 365 401 518 572 1.096
2025/202620.053 1.126 794 1.020 1.592 2.081 2.789 2.562 1.985 1.690 2.591 896 927
2026/2027583 583 0 0 0 0 0 0 0 0 0 0 0
Totale 49.191